EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications

Olivia M Burke, Brianna Sa, David Alvarez Cespedes, Antonella Tosti

Skin Appendage Disorders · 14.02.2025 · 11 (5) · 416-423

DOI: 10.1159/000544023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Skin Appendage Disorders, online erschienen am 14.02.2025. Verfasst von Olivia M Burke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an innovative class of medications primarily used to manage type 2 diabetes and obesity. These agents not only improve glycemic control but also promote significant weight loss and reduce cardiovascular risk. Summary: GLP-1RAs are associated with various dermatologic effects, including injection-site reactions and immune-mediated responses such as hypersensitivity, urticaria, and bullous pemphigoid. “Ozempic face,” a term describing facial fat loss, has gained media attention due to its cosmetic implications. Additionally, hair loss, particularly in the form of telogen effluvium, has been observed, potentially linked to rapid weight loss from GLP-1RA use. Emerging evidence also highlights the therapeutic potential of GLP-1RAs in enhancing wound healing and treating inflammatory skin conditions like psoriasis. Key Messages: With the increasing use of GLP-1RAs for weight management, clinicians should remain alert to dermatologic side effects and consider appropriate dermatologic consultations when needed. Further research is essential to optimize the safe and effective use of GLP-1RAs, ensuring therapeutic benefits are maximized while minimizing adverse dermatologic outcomes.

Schlagwörter

Stichwörter der Autor:innen

AlopeciaDermatologic effectsGlucagon-like peptide-1 receptor agonistGlucagon-like peptide-1 receptor agonistsOzempic

Autor:innen und Institutionen

  • Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Zitieren

APA

Burke, O. M., Sa, B., Cespedes, D. A., & Tosti, A. (2025). Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disorders, 11(5), 416-423. https://doi.org/10.1159/000544023

Vancouver

Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disorders. 2025;11(5):416-423. doi:10.1159/000544023

BibTeX
@article{Burke2025,
  author = {Burke, Olivia M and Sa, Brianna and Cespedes, David Alvarez and Tosti, Antonella},
  title = {Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications},
  journal = {Skin Appendage Disorders},
  year = {2025},
  volume = {11},
  number = {5},
  pages = {416--423},
  doi = {10.1159/000544023}
}
Kostenlos starten →